Snehal Patel Acquires 6,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Rating) CEO Snehal Patel purchased 6,000 shares of Greenwich LifeSciences stock in a transaction that occurred on Thursday, April 21st. The stock was purchased at an average price of $16.09 per share, with a total value of $96,540.00. Following the completion of the purchase, the chief executive officer now directly owns 1,216,929 shares in the company, valued at $19,580,387.61. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Snehal Patel also recently made the following trade(s):

  • On Tuesday, April 19th, Snehal Patel purchased 6,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $16.74 per share, with a total value of $100,440.00.
  • On Friday, February 11th, Snehal Patel bought 5,500 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $19.80 per share, with a total value of $108,900.00.
  • On Friday, February 4th, Snehal Patel bought 5,000 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $19.59 per share, with a total value of $97,950.00.

Shares of GLSI stock opened at $15.87 on Friday. Greenwich LifeSciences, Inc. has a twelve month low of $15.52 and a twelve month high of $48.96. The business has a fifty day simple moving average of $19.58 and a 200 day simple moving average of $25.79.

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its position in shares of Greenwich LifeSciences by 9.2% during the 4th quarter. BlackRock Inc. now owns 237,959 shares of the company’s stock worth $5,790,000 after buying an additional 20,105 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Greenwich LifeSciences by 18.4% during the 4th quarter. Geode Capital Management LLC now owns 67,420 shares of the company’s stock worth $1,640,000 after buying an additional 10,501 shares during the last quarter. State Street Corp lifted its position in shares of Greenwich LifeSciences by 9.4% during the 4th quarter. State Street Corp now owns 65,309 shares of the company’s stock worth $1,589,000 after buying an additional 5,595 shares during the last quarter. Millennium Management LLC increased its holdings in Greenwich LifeSciences by 101.4% in the 4th quarter. Millennium Management LLC now owns 30,414 shares of the company’s stock worth $740,000 after purchasing an additional 15,316 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Greenwich LifeSciences in the 4th quarter worth about $730,000. Institutional investors and hedge funds own 6.25% of the company’s stock.

Separately, Zacks Investment Research upgraded Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research report on Thursday.

Greenwich LifeSciences Company Profile (Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery.

Read More

Insider Buying and Selling by Quarter for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.